SpyGlass Pharma (Nasdaq: SGP) announced that its executive management team will participate in three upcoming healthcare investor conferences. Fireside chats and one-on-one meetings are scheduled at Stifel in New York on November 12, 2026, Jefferies in London on November 17, 2026, and Citi in Miami on December 3, 2026. Live webcasts and replays of the fireside chats will be available through the company’s Investor Relations website.
SpyGlass Pharma (SGP) announced four-year interim results from its first-in-human trial of the Bimatoprost Drug Pad-IOL System, or BIM-IOL System.
The trial involves patients with mild-to-moderate open angle glaucoma or ocular hypertension undergoing routine cataract surgery. Among 21 evaluable patients, mean intraocular pressure, the pressure inside the eye, fell 37% across all three dose groups, from 25.1 ± 2.5 mmHg at baseline after washout to 15.9 ± 2.8 mmHg. At four years, 86% (18 of 21) remained off all topical pressure-lowering drops, and 90% maintained best corrected distance visual acuity of at least 20/25. No product-related adverse events were reported.
The trial was designed to evaluate safety and efficacy over seven years; the company plans to follow patients through 2029.
SpyGlass Pharma (SGP) acquired Advanced Vision Science from Santen Pharmaceutical for approximately $13 million in cash, securing intraocular lens manufacturing capacity.
The purchase covers all outstanding common shares of AVS, which supplies lenses for SpyGlass Pharma’s two Phase 3 trials evaluating the BIM-IOL System. Intraocular lenses, or IOLs, are lenses implanted inside the eye. SpyGlass Pharma plans to use the manufacturing capability to accelerate development of additional lens options for its drug delivery system, including toric and extended depth-of-focus lenses.
Under the agreement, AVS will exclusively manufacture and supply several IOL types to Santen for commercialization in Japan. AVS will also continue licensing its acrylic lens material to Bausch + Lomb for the enVista IOL line and manufacturing products for other global IOL companies.
SpyGlass Pharma (SGP) will participate in three investor conferences in September 2026, featuring meetings, a fireside chat and a corporate presentation.
Events include the Wells Fargo 21st Annual Healthcare Conference on September 9, Citi’s 2026 Biopharma Back to School Conference on September 10, and the H.C. Wainwright 28th Annual Global Investment Conference on September 14. Webcasts for the Citi fireside chat and H.C. Wainwright presentation will be available via the company’s Investor Relations website.
SpyGlass Pharma (Nasdaq: SGP) reported second quarter 2026 results and clinical updates. The company held $234.2 million in cash, cash equivalents and short-term investments as of June 30, 2026, which it expects will fund planned operations through 2028.
Enrollment in the parallel registrational Phase 3 trials of the Bimatoprost Drug Pad-IOL System (BIM-IOL System) remains on track, with completion expected in 2027, and a first-in-human trial of the Bimatoprost-Drug Ring System (BIM-DRS) is expected to start in the second half of 2026. In May 2026, the AMA approved a dedicated add-on Category III CPT code (+1090T) for use with established cataract surgery codes, creating a specific reimbursement pathway for the BIM-IOL System. Second quarter 2026 research and development expenses were $10.9 million and general and administrative expenses were $11.0 million, leading to a net loss of $19.9 million, or $(0.59) per share.
SpyGlass Pharma (Nasdaq: SGP) appointed Shannon Treviño as general counsel. She is a healthcare-focused legal executive with corporate, M&A, and securities experience, including guiding Inari Medical through its $4.9 billion acquisition by Stryker. The hire comes as SpyGlass advances its BIM-IOL System through Phase 3 trials and prepares for potential commercialization.
SpyGlass Pharma (Nasdaq: SGP) appointed Mike Pinder as vice president, marketing. He brings over 20 years of ophthalmology commercial launch experience, including roles at Astellas, Novartis, and Johnson & Johnson.
Pinder will build and lead marketing as SpyGlass advances its BIM-IOL System through Phase 3 trials toward potential FDA-approved commercialization.
SpyGlass Pharma (Nasdaq: SGP) announced that its executive management will participate in three upcoming investor events focused on healthcare and ophthalmology.
These include the Stifel 2026 Virtual Ophthalmology Forum on May 26, the Jefferies Global Healthcare Conference on June 4, and the Goldman Sachs 47th Annual Global Healthcare Conference on June 10, 2026. All sessions feature fireside chats or a corporate presentation, with live webcasts and replays available on the company’s investor relations website.
SpyGlass Pharma (Nasdaq: SGP) announced AMA approval of a new add-on Category III CPT code +X659T for attachment and insertion of an intraocular lens prosthesis-mounted drug-eluting implant, based on its Bimatoprost Drug Pad-IOL (BIM-IOL) System, used with existing cataract surgery codes.
The BIM-IOL System targets elevated intraocular pressure in open-angle glaucoma or ocular hypertension patients with cataracts and is in two Phase 3 trials, with enrollment expected to complete in 2027.
SpyGlass Pharma (Nasdaq: SGP) reported first quarter 2026 results and pipeline progress. Cash, cash equivalents and short-term investments were $251.0 million as of March 31, 2026, expected to fund operations through 2028.
Phase 1/2 BIM-IOL data showed 34% mean IOP reduction at 78-mcg, 98% of patients free from topical IOP-lowering drops and 100% achieving BCDVA 20/32 or better, with a safety profile comparable to routine cataract surgery. Parallel Phase 3 BIM-IOL trials SGP-005 and SGP-006 have begun surgeries, with enrollment completion expected in 2027. The BIM-DRS first-in-human trial is planned for the second half of 2026. Net loss was $13.8 million, or ($0.69) per share, versus $8.8 million, or ($3.96) per share, a year earlier.